ArticleScientific reports2025
Netrin-1 as a molecular mediator linking APOE ε4 to alzheimer's disease pathogenesis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurodegenerative diseases and environmental risk factors: an overview of the available scientific evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The ɛ4 allele of the apolipoprotein E (APOE) gene stands as the most significant genetic risk factor for Alzheimer's disease (AD), although the underlying mechanism linking APOE to the disease remains elusive. Netrin-1, has been found to inhibit Aβ production, reduce neuroinflammation, and regulate synaptic plasticity, thereby playing a role in AD. Recent reports suggest that Netrin-1 could be a key protein connecting APOE ɛ4 with Aβ and tau tangles. This study aims to investigate whether APOE regulates the expression or function of Netrin-1, thus influencing the risk of developing AD. The serum levels of Netrin-1 were notably reduced in patients with AD compared to healthy individuals, whereas interleukin-6 (IL-6) concentrations were higher in the AD group. patients harboring the APOE ε4 allele exhibited a more pronounced decrease in Netrin-1 compared to those with other APOE genotypes. Furthermore, a correlation was observed between Netrin-1 concentrations and APOE allelic variations. Our results imply that Netrin-1 is a key player in the cognitive decline observed in AD and potentially contributes to the APOE-driven cognitive impairment process. This association is tightly linked to inflammatory factors, suggesting that Netrin-1 may serve as a crucial biomarker for the prognosis and therapeutic intervention of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.